1,031
Views
35
CrossRef citations to date
0
Altmetric
Review

Advances in dopamine receptor agonists for the treatment of Parkinson’s disease

, &
Pages 1889-1902 | Received 02 Feb 2016, Accepted 28 Jul 2016, Published online: 29 Aug 2016
 

ABSTRACT

Introduction: Dopamine agonists (DA) are a class of agents which directly stimulate dopamine receptors mimicking the endogenous neurotransmitter dopamine. At first used as adjunctive therapy in the advanced phases of the disease, over the years a significant role was found for DA monotherapy as a first approach in the initial stage of Parkinson’s disease (PD). Several reviews have already reported efficacy and safety of DA in PD and differences between DA and levodopa. Therefore the objective of this review is to gather recent updates in DA therapy. A thorough knowledge of recent literature evidences, would help clinician in the management of treatment with DA.

Areas covered: Our review investigates recent updates on DA therapy, the role of these compounds in controlling non-motor symptoms (NMS) as well as new formulations under clinical evaluation and newly emerged post-marketing safety considerations. A literature search has been performed using Medline and reviewing the bibliographies of selected articles.

Expert opinion: DA represents a very important option in the treatment of PD, even though there are still some criticisms and unmet needs. A better knowledge of dopamine receptors could lead to identification of new compounds able to better balance clinical efficacy and side effects.

Article highlights

  • DA remain very useful compounds in the treatment of PD. The new once a day and the transdermal formulations of DA made the use of the agonists easier increasing compliance of patients and adherence to treatment.

  • New formulations of DA are currently under investigation for the treatment of early morning akinesia, post prandial OFF, unpredictable OFF, which dramatically impact on patients’ quality of life.

  • The long clinical experience with DA agonists has also arised new complications like DAWS and heart failure and better defined aspects of Dopamine Disregulation Syndrome

  • It is crucial that DA would be properly used in order to optimize benefits and minimize both short-term and long-term adverse effects.

This box summarizes key points contained in the article.

Declaration of interest

F Stocchi has been a consultant to TEVA, Novartis, GlaxoSmithKline, Lundbeck, Merck Serono, Merck Sharp & Dohme, UCB Pharma, ChiesiPharma, IMPAX, Newron, Zambon, Cynapsus and Britannia. He has also received research funding from Novartis and GlaxoSmithKline as well as received honoraria for educational symposia and consultancy to GlaxoSmithKline. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper is not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.